Double Digit NASDAQ Stock Winners: PROG, FAMI, ALZN
7:38 am Friday, October 01st, 2021
Following are major stock gainers on Nasdaq in Thursday’s trading session:
Progenity, Inc. (NASDAQ:PROG) was the active stock gainer on Thursday and soared 41% to $1.52. Progenity, Inc., a biotechnology company, provides develops and commercializes molecular testing products in the United States. It offers Innatal, a noninvasive prenatal screening test offered to women early in pregnancy to screen for chromosome abnormalities, such as down syndrome, trisomy 18, trisomy 13, and sex chromosome disorders through the analysis of cell-free DNA; Preparent that screens for carrier status of hereditary diseases prior to or early in pregnancy; and Riscover, a hereditary cancer screen that analyzes 31 genes associated with inherited risk of 12 types of cancers, including the BRCA1/2 genes for hereditary breast, ovarian, colorectal, endometrial, pancreatic, and other cancer syndromes, as well as for the five genes associated with Lynch syndrome.
Farmmi, Inc. (NASDAQ:FAMI) stock surged 36% to $0.46. Farmmi, Inc., together with its subsidiaries, processes and sells agricultural products in China, the United States, Japan, Canada, Europe, Korea, and the Middle East. The company offers shiitake and Mu Er mushrooms; and other edible fungi products, including bamboo fungi, agrocybe aegerila, pleurotus eryngii, grifola frondosa, coprinus comatus, and hericium erinaceus. It also operates Farmmi Jicai, an online store that sells edible fungi products under Forasen and Farmmi Liangpin brands. In addition, the company exports dried whole and sliced shiitake mushrooms, and dried black fungus to Israel. It offers its products to restaurants, cafeterias, and local specialty stores, as well as through distributors. Farmmi, Inc. was incorporated in 2015 and is headquartered in Lishui, China.
Alzamend Neuro, Inc. (NASDAQ:ALZN) moved up 35% to $3.08 after the company received a written response to its meeting request regarding the FDA’s Type B Pre‑Investigational New Drug (Pre-IND) application. Today’s response provides a path for its planned clinical development of AL002, the Company says. AL002 uses a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s. The FDA agreed to Alzamend’s proposed combined Phase 1/2 study.
